Volume 29, Issue 5, 2020
DOI: 10.24205/03276716.2020.1095
The Effect of Terlipressin On Posthepatectomy Recovery Among Patients with Different Stages of Fibrosis: A Retrospective Study
Abstract
Aim: Terlipressin, a kind of vasopressin analogue, has been used for reducing portal tension and increasing the kidney perfusion. This study aimed to find out how terlipressin could affect posthepatectomy recovery among patients with different stages of fibrosis.
Methods: A total of 106 patients were included retrospectively, with 54 patients in terlipressin group and others in control group. Terlipressin was administered after in terlipressin group postoperatively. Comprehensive comparisons, including clinical outcomes, laboratory tests and adverse drug effects, were conducted not only between two groups, but also between patients with different stages of fibrosis. The pharmacological efficacy on patients with high and low stages of fibrosis was also investigated.
Results: Patients with terlipressin from all stages of fibrosis had a significantly less median abdominal drainage volume on the first, second, third postoperative day and all three days (p<0.001, p<0.001, p=0.001, p<0.001), more urine output on the third, fourth, fifth day and first five days overall (p=0.018, p<0.001, p<0.001, p<0.001) and shorter duration of abdominal drainage retainment (p<0.001), while lower creatine level was only observed on the fourth and fifth day (p=0.044, p=0.047) within the high stage fibrosis subgroup analysis. However, no significant difference was found in the pharmacological efficacy between distinct severities of fibrosis.
Conclusion: The use of terlipressin was associated with better recovery of patients with all stages of fibrosis by reducing abdominal drainage, increasing urine output and accelerating abdominal drainage removal, and offered a better protection of renal function in patients with severer fibrosis.
Keywords
posthepatectomy recovery, terlipressin, liver fibrosis, pharmacological efficacy